You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Cell-based screening of combinatorial siRNA libraries
SBC: CYNTELLECT, INC. Topic: N/ADESCRIPTION (provided by applicant): RNA interference (RNAi) is a specific post-transcriptional gene silencing pathway mediated by intracellular dsRNAs of 21-23 bp in length known as small interfering RNA (siRNA). Since the recent discovery of effective siRNA-mediated gene silencing in mammalian cells, there has been significant validation and enormous interest in the approach from both academic a ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Endoscopic Detection of Fluorescein for Sentinel Lymph Node Biopsy
SBC: VESTAN INC Topic: N/ADESCRIPTION (provided by applicant): The objective of this grant is to develop fluorescence endoscopy instrumentation to facilitate the surgical management of breast cancer, with possible application to other types of cancer. The specific aims for this project are to develop a combination holographic notch filter adapter and switchable high-intensity LED light source adapter for currently availabl ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100
SBC: NEONC TECHNOLOGIES INC Topic: 102Project Summary Abstract Many pharmaceutical agents are highly potentbut are unable to exert substantial therapeutic activity against disorders of the brainbecause the blood brain barrierBBBeffectively prevents their access to the site of intracerebral diseaseFor examplethe majority of glioblastoma patientsdespite the best efforts of current medical caredie within two years after diagnosisHencethe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
O-Glycan-dependent Immunotherapy for Cancer
SBC: GlyTR Therapeutics, Inc. Topic: 102Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
In vitro and in vivo evaluation of elephant p53 (EP53) protein nanoparticles for pediatric osteosarcoma
SBC: Peel Therapeutics, Inc Topic: 102PROJECT SUMMARY ABSTRACT PEEL TherapeuticsIncis a life sciences company created to impact the lives of people with cancerBased on the research efforts of DrJoshua Schiffman and DrAvi SchroederPEEL TherapeuticsPEELhas created liposomal nanoparticles that have been loaded with elephant pEPproteins as a new class of anti cancer protein therapeuticsElephants have an unexpectedly low rate of cancer giv ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD
SBC: ONL Therapeutics, Inc. Topic: NEIPROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated with exposure to cigarette smokeCSand high fat dietsHFDWhile effective treatment is available for neovascular AMDthe AREDS II antioxidant vitamins are the only proven treatment for intermediate dry AMDUn ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery
SBC: Cavatar LLC Topic: NCIPROJECT SUMMARY This proposal aims to develop a novel caveolae targeting antibody for rapid clinical translationIts long term objective is to develop the caveolae pumping systeman active transendothelial transport pathwayto provide an effective solution to the delivery and toxicity problem of systemically administered chemotoxinsWork will be based on the current proprietary mouse monoclonal antibo ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effects
SBC: VALA SCIENCES, INC. Topic: 101Neurodevelopmental diseasesNDDsAutism Spectrum DisorderASDIntellectual DisabilitiesBipolar disordersand Schizophreniaetcare prevalent and due to errors in neurodifferentiation and neurocircuitryWhile NDDsin many casesare due to inherited mutationsevidence is mounting that prenatal exposure to environmental toxicants also cause NDDs via disruption of epigeneticse gmodifications of histoneshistone t ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity
SBC: SignalRx Pharmaceuticals Inc. Topic: 102Three CDKinhibitors were recently approved to treat breast cancerBrCAin combination regimentsDespite significant clinical activitytreatment of BrCA patients with these combinations does not result in a durable responseHencethere is an unmet medical need to develop targeted therapeutic agents which will augment the activity of CDKinhibitors in BrCA and other CDKcyclin D Myc dependent malignanciesA ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Low-cost custom microarray synthesis
SBC: BIODISCOVERY LLC Topic: N/ADESCRIPTION (provided by applicant): In this project our goal is to develop and commercialize a very low cost microarray chip fabrication technology to reduce the cost by as much as a factor of ten and enable the use of microarrays by groups who can not afford the current generation of microarrays. Our technology combines the standard acid labile DMT protection group containing nucleophosphoramidi ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health